CPC Clinical Research   Report issue

For profit Phase 2 Phase 3
Founded: Aurora CO United States (1989)

Organization Overview

First Clinical Trial
2014
NCT02227368
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

CPC Clinical Research | CPC Clinical Research (Collorado, USA)

Active Ingredients

Drugs in Phase 3 Trials (2)

heparin (liquaemin) (1 trial)

recombinant nematode anticoagulant protein c2 (1 trial)

Drugs in Phase 2 Trials (2)

dvc1-0101 (1 trial)

ticagrelor (brilinta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Intermittent Claudication (Phase 2)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4